MedPath

Lanicemine

Generic Name
Lanicemine
Drug Type
Small Molecule
Chemical Formula
C13H14N2
CAS Number
153322-05-5
Unique Ingredient Identifier
9TMU325RK3

Overview

Lanicemine has been used in trials studying the treatment and basic science of Depression, Major Depressive Disorder, and Treatment Resistant Major Depressive Disorder.

Indication

No indication information available.

Associated Conditions

No associated conditions information available.

Research Report

Published: May 23, 2025

Lanicemine (DB11889): A Comprehensive Pharmacological and Clinical Development Profile

1. Introduction to Lanicemine

1.1. Overview and Chemical Properties

Lanicemine is an investigational small molecule drug, identified by the DrugBank Accession Number DB11889, which has been the subject of numerous clinical trials, primarily focusing on its potential as a treatment for depressive disorders.[1] Its Chemical Abstracts Service (CAS) Registry Number is 153322-05-5 for the free base form.[2]

Lanicemine is known by several synonyms, reflecting its journey through different stages of development and by various research groups. These include AZD6765, its development code under AstraZeneca; AR-R 15896AR, an earlier development designation; (αS)-phenyl-2-pyridineethanamine, its chemical name; and BHV-5500, the code used by Biohaven Pharmaceuticals.[1] The dihydrochloride salt form of Lanicemine is also documented, with CAS Number 153322-06-6.[19]

The molecular formula for the free base of Lanicemine is C13​H14​N2​.[1] Its average molecular weight is approximately 198.269 g/mol, often rounded to 198.27 g/mol.[1] The dihydrochloride salt form has a molecular weight of 271.19 g/mol.[19]

In its physical form, Lanicemine free base has been described as a neat oil.[2] The dihydrochloride salt is typically an off-white to light yellow solid.[19] Regarding solubility, the free base form is soluble in organic solvents such as ethanol, dimethyl sulfoxide (DMSO), and dimethylformamide. The dihydrochloride salt exhibits good solubility in DMSO and water, with aqueous solubility reported as ≥100 mg/mL.[2] Specific solubility data indicates approximately 20 mg/mL in ethanol, 30 mg/mL in DMSO, and 5 mg/mL in dimethylformamide for the free base, and ≥100 mg/mL in water and 240 mg/mL in DMSO (requiring sonication) for the dihydrochloride salt.[2]

Table 1: Lanicemine Identifiers and Basic Properties

Continue reading the full research report

FDA Drug Approvals

Approved Product
Manufacturer
NDC Code
Route
Strength
Effective Date
No FDA approvals found for this drug.

EMA Drug Approvals

Approved Product
Authorization Holder
Status
Issued Date
No EMA approvals found for this drug.

HSA Drug Approvals

Approved Product
Manufacturer
Approval Number
Dosage Form
Strength
Approval Date
No HSA approvals found for this drug.

NMPA Drug Approvals

Approved Product
Company
Approval Number
Drug Type
Dosage Form
Approval Date
No NMPA approvals found for this drug.

PPB Drug Approvals

Approved Product
Registration No.
Company
Licence No.
Strength
Registration Date
No PPB approvals found for this drug.

TGA Drug Approvals

Approved Product
ARTG ID
Sponsor
Registration Type
Status
Registration Date
No TGA approvals found for this drug.

Health Canada Drug Approvals

Approved Product
Company
DIN
Dosage Form
Strength
Market Date
No Health Canada approvals found for this drug.

CIMA AEMPS Drug Approvals

Approved Product
Company
Registration Number
Pharmaceutical Form
Prescription Type
Status
No CIMA AEMPS (Spain) approvals found for this drug.

Philippines FDA Drug Approvals

Approved Product
Company
License Number
Dosage Form
Strength
Approval Date
No Philippines FDA approvals found for this drug.

Saudi SFDA Drug Approvals

Approved Product
Company
License Number
Dosage Form
Strength
Approval Date
No Saudi SFDA approvals found for this drug.

Malaysia NPRA Drug Approvals

Approved Product
Company
Registration Number
Dosage Form
Strength
Approval Date
No Malaysia NPRA approvals found for this drug.

UK EMC Drug Information

Medicine Name
MA Holder
MA Number
Pharmaceutical Form
Active Ingredient
Authorization Date
No UK EMC drug information found for this drug.

Help Us Improve

Your feedback helps us provide better drug information and insights.

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.